MK-677 vs Tesa/IPA Protocol
Well Studied vs Limited Research
monitor Researched · 90% Both affect GH release; combination may be excessive and affect glucose.
Molecular Data
MK-677 Tesa/IPA Protocol
Weight 624.77 Da —
Half-life ~24 hours —
Type Non-peptide ghrelin receptor agonist Dual GH secretagogue combination
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Tesa/IPA Protocol
01 Synergistic GH release from dual pathways
02 More physiological pulsatile GH secretion
03 Tesamorelin's proven lipodystrophy benefits
04 Ipamorelin's clean side effect profile
05 Does not significantly affect cortisol or prolactin
06 Single injection convenience
07 May improve body composition, sleep, and recovery
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Tesa/IPA Protocol
200-500mcg total blend per injection / Once daily (evening preferred) or twice daily for advanced protocols
Standard protocol (5/5 blend) 200-400mcg total Once daily (evening)
Enhanced protocol (10/3 blend) 300-500mcg total Once daily (evening)
Twice daily (advanced) 200-300mcg per dose Morning and evening
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Tesa/IPA Protocol
Injection site reactions (redness, itching)
Water retention (usually transient)
Tingling or numbness in extremities
Joint stiffness
Increased hunger (Ipamorelin effect)
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components
Research Evidence
MK-677 Tesa/IPA Protocol
Status Well Studied Limited Research
References 7 studies 4 studies
Latest July 2024 June 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.